Lyvispah®(baclofen) oral granules product discontinuation
Dear Patients, Caregivers and Healthcare practitioners:
As of June 30, 2025, Amneal has discontinued its promotion and distribution of Lyvispah® (baclofen) oral granules.
The product is no longer commercialized by Amneal and will remain available at pharmacies only while the existing stock lasts.
If you are a patient currently prescribed Lyvispah® (baclofen), we suggest contacting your healthcare provider to explore the best available baclofen options through other manufacturers. Your healthcare provider can provide you with personalized guidance to ensure you will receive the most effective care.
We are here for you! If you need to reach us, you may do so in any of the following ways:
Report an adverse event (or adverse experience), product complaint or medical inquiry
If you are in the U.S. and currently experiencing a life-threatening event, please immediately call 9-1-1.
To report an adverse event (or adverse experience), product complaint or medical inquiry related to an Amneal Product:
Contact the Amneal Drug Safety team at 877.835.5472, option 3 or at DrugSafety@amneal.com.
You may also contact FDA at 1.800.FDA.1088 or www.fda.gov/medwatch
For all other inquiries
Please contact us by phone on 877.835.5472 and listen to the prompt most closely aligned to your inquiry.
You may also visit our global company website at www.amneal.com.
©2025 Amneal Pharmaceuticals LLC. All rights reserved. PP-ADW-LYVI-US-0046 04/2025